Real-World Outcomes of First-Line Palbociclib Plus Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer in Japan: A Single-Center Retrospective Study.

Oncol Res · 2025 · PMC12774543 · PMID 41502524

Europe PMC DOI

hedged sentence

0.0830

closest p · 1.7× alpha

0.0830

boldest claim

The sentences

did not reach statistical significancep = 0.083so close (0.05 < p ≤ 0.1)

Additionally, de novo metastatic disease tended to be more frequent in the PS 2–3 group, although the difference did not reach statistical significance ( p = 0.083).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.